Prognostic factors influencing the selection of bevacizumab combined with chemotherapy in patients with HER2-negative metastatic breast cancer in routine clinical practice: Oncosur-Avalox—Observational cross-sectional study
| Autor: | Isabel Gallegos Sancho, Maria Dolores Torregrosa, Javier Cassinello, Andrés García-Palomo, Cristina Llorca, M. Mendez, Ramon Perez-Carrion, Gustavo Catalan, Esperanza J. Carcache de Blanco, Rosa Llorente, Antonia Perelló, Maria Jose Garcia Lopez, Coralia Bueno, Antonio J. Fernández, Xabier Mielgo Rubio, Elena Galve Calvo, Luis Manso, Jose Ignacio Chacon, Hernán Cortés-Funes, Inaki Alvarez |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Chemotherapy Bevacizumab Cross-sectional study business.industry medicine.medical_treatment HER2 negative medicine.disease Metastatic breast cancer Internal medicine medicine Routine clinical practice Observational study In patient business medicine.drug |
| Zdroj: | Web of Science |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2013.31.15_suppl.e12020 |
| Popis: | e12020 Background: Combining bevacizumab (BEV) with chemotherapy (CT) improves survival in HER2-negative metastatic breast cancer (MBC). We investigated the influence of age, ECOG, hormonal status, number of sites, location of metastases and patient decision on the selection of BEV combined with CT in MBC. Methods: Observational cross-sectional multicenter study in patients with HER2- negative MBC who have received first-line CT with BEV. Results: 219 patients were included: median age 51(44-63) yr; ECOG: 0=53%; 60.4% pre-menopausic; 23.9% triple-negative (TN);76.2 % hormone receptor positive (HR+).Metastatic disease: ≥3 sites=39.2% (TN: 22%; HR+: 43.9%); location: 45.2% bone, 37.4% liver, 30.1% lung. Most frequent BEV combinations were paclitaxel/BEV(60.7%) and docetaxel/BEV(12.8%); median no. of CT cycles: 6 (5- 8). A disease-free survival (DFS) ≥12 months was achieved by 82.8%; TN: 78.9%; HR+: 83.3%. Overall response rate (ORR) was 62.7%: 53.6% partial response (PR), 9.1% complete response (CR); 25.4% stable disease (SD) and 7.2% disease progression (4.8% non evaluated). TN:ORR 54.2% (47.9% PR), clinical benefit 80% (27.1% SD); HR+:ORR 65.8% (55.7% PR), clinical benefit 89.9% (24.1% SD). 66.2% presented at least one toxicity, mainly grade 1-2; 32% BEV-related: only 3 grade 3 toxicities; no grade 4. Receiving adjuvant hormonal therapy was associated to DFS ≥12 months (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|